Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE EPAS1 was detected in all of the RCC cell lines examined. 11301389 2001
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 AlteredExpression disease BEFREE Nox4 is critical for hypoxia-inducible factor 2-alpha transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma. 16230378 2005
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. 15592504 2005
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma. 20032376 2009
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 AlteredExpression disease BEFREE HIF-1α, HIF-2α and CAIX were up-regulated in 88.2% (15/17), 100% (17/17) and 88.2% (15/17) of tumors respectively and their expression is independent of VHL status. hnRNP A2/B1 and osteopontin expression was variable in CCRCCs and had no association with VHL genetic status. 20978319 2010
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease CTD_human Two correlated variants (r² = 0.99 in controls), rs11894252 (P = 1.8 × 10⁻⁸) and rs7579899 (P = 2.3 × 10⁻⁹), map to EPAS1 on 2p21, which encodes hypoxia-inducible-factor-2 alpha, a transcription factor previously implicated in RCC. 21131975 2011
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 AlteredExpression disease BEFREE HIF-1α, HIF-2α and CAIX were up-regulated in 88.2% (15/17), 100% (17/17) and 88.2% (15/17) of tumors respectively and their expression is independent of VHL status. hnRNP A2/B1 and osteopontin expression was variable in CCRCCs and had no association with VHL genetic status. 21547579 2011
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 GeneticVariation disease BEFREE Two correlated variants (r² = 0.99 in controls), rs11894252 (P = 1.8 × 10⁻⁸) and rs7579899 (P = 2.3 × 10⁻⁹), map to EPAS1 on 2p21, which encodes hypoxia-inducible-factor-2 alpha, a transcription factor previously implicated in RCC. 21131975 2011
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Further exploration of 8q gain, 14q loss, MYC, HIF1A and EPAS1 (HIF2α) as molecular markers of tumor behavior and prognosis could aid in personalizing medicine for patients with clear-cell renal cell carcinoma. 21725288 2011
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 GeneticVariation disease BEFREE In follow-up of a recent genome-wide association study (GWAS) that identified a locus in chromosome 2p21 associated with risk for renal cell carcinoma (RCC), we conducted a fine mapping analysis of a 120 kb region that includes EPAS1. 22113997 2012
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 AlteredExpression disease BEFREE We first evaluated the protein expression of HIF1α and HIF2α in 15 different clear cell renal carcinoma cell lines established from patient tumors in our laboratory. 23178531 2012
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Although HIF2α is an oncogene in ccRCC, some of its targets might have tumor suppressive activity. 21725364 2012
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients. 23378636 2013
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE To investigate the oncolytic efficacy of a highly virulent (velogenic) Newcastle disease virus (NDV) in the presence or absence of HIF-2α, renal cell carcinoma (RCC) cell lines with defective or reconstituted wild-type (wt) von Hippel-Lindau (VHL) activity were used. 23506478 2013
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE CPT demonstrated striking inhibition of both HIF-1α and HIF-2α accumulation in von Hippel-Lindau (VHL)-defective ccRCC cells, but surprisingly failed to inhibit protein levels of HIF-2α-dependent target genes (VEGF, PAI-1, ET-1, cyclin D1). 24136229 2013
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE HIF-2α is stabilized in von Hippel-Lindau (VHL)-deficient renal cell carcinoma through mechanisms that require ongoing mRNA translation. 22869144 2013
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 AlteredExpression disease BEFREE In this issue of Cancer Discovery, Mathew and colleagues report that miR-30c-2-3p and miR-30a-3p downregulation in ccRCC promotes increased expression of HIF2α. 24402943 2014
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 AlteredExpression disease BEFREE In determining the critical functions for HIF2α expression in RCC cells, the NADPH oxidase NOX4 has been identified, but the pathogenic contributions of NOX4 to RCC have not been evaluated directly. 24755467 2014
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE This indicates that current understanding of the exact roles of HIF1α and HIF2α is incomplete and that further research is required to determine the diverse roles of HIF1α and HIF2α in ccRCC. 24916472 2014
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE We demonstrate that HIF2α promotes lipid storage, ER homeostasis, and cell viability in ccRCC via upregulation of the LD coat protein PLIN2, revealing a novel function for the well-documented "clear-cell" phenotype and identifying ER stress as a targetable vulnerability created by HIF2α/PLIN2 suppression in this common renal malignancy. 25829424 2015
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE Herein, we provide mechanistic evidence that HIF-2α can be degraded in cytoplasm under hypoxic conditions via the 26S proteasome and that MDM2 is the E3 ligase which induces the hypoxic degradation of HIF-2α in PI-3K-dependent manner in VHL-deficient RCC cells. 25578041 2015
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE HIF2α is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma. 26439684 2015
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE This study indicates that autophagy has an anticancer role in ccRCC tumorigenesis, and suggests that constitutive autophagic degradation of HIF2α is a novel tumor suppression mechanism. 24998849 2015
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE The hypoxia-inducible factors HIF1α and HIF2α play a crucial role in ccRCC initiation and progression. 27507852 2016
Conventional (Clear Cell) Renal Cell Carcinoma
0.400 Biomarker disease BEFREE These studies validate HIF2α as a therapeutic target in ccRCC, reveal variable sensitivity to HIF2α antagonism, and provide the foundation for predictive biomarker-driven clinical trials. 27728802 2016